Phase 2 trials
中等规模的人体试验已测量剂量与效果。它不是已获许可的药品。
本页内容尚不完整
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
证据有多强
它攀登到了哪一级
每种药物都要攀登同一架阶梯。大多数化合物从未到达顶端,其所处位置决定了其主张能有多大的依据。
- 已获许可的药物
监管机构已审查这些试验,并批准其用于特定用途。
- Phase 3
大型随机试验,通常有数千人,与安慰剂或标准治疗对照。
- Phase 2: Eloralintide
中等规模试验,在患有相应疾病的人群中测量剂量与效果的关系。
- Phase 1 and early human studies
首次在人体中进行的研究:安全性以及身体如何处理该物质。
- 细胞与动物
实验室及动物研究。动物实验的结果不等同于人体结果。
- 10
- PubMed 上的论文
- 7
- 其中以人为对象的研究
- 3
- 随机试验
- 6
- 综述
文献数量只说明发表了多少,并不说明结果如何。在 PubMed 上统计的数量: 2026-11-16
处理与复溶
从粉末到测量好的样品
对任何冻干小瓶都是同样的四个步骤。仅指实验室操作,并非用于人体。
1. 阅读小瓶标签
标签给出小瓶中肽的质量,单位为毫克。这个数字是所有计算的起点。
2. 加入稀释剂
将量好的稀释剂沿玻璃壁缓慢加入。轻轻旋转;摇晃可能损伤肽。
3. 计算浓度
浓度等于质量除以体积:10 毫克溶于 2 毫升即为每毫升 5 毫克。
4. 量取样品
体积等于所需质量除以浓度。在 U-100 注射器上,1 毫升即 100 单位。
下方的计算器会完成运算并显示计算过程。
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Eloralintide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Eloralintide; no amount here is a recommendation.
Eloralintide: PubMed 上的文献
What PubMed held for Eloralintide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 10
- papers
- 7
- in humans
- 3
- clinical trials
- 3
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Randomized trialBriere DA, Qu H, Lansu K, et al. Molecular metabolism, 2025. PMID 41109426
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Randomized trialBillings LK, Hsia S, Bays H, et al. Lancet (London, England), 2025. PMID 41207310
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Randomized trialBhattachar S, Tham LS, Tidemann-Miller B, et al. Diabetes, obesity & metabolism, 2026. PMID 41559929
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis
ReviewKamrul-Hasan ABM, Khalil I, Mahajan K, et al. Endocrinology, diabetes & metabolism, 2026. PMID 42175595
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
ReviewBailey CJ, Flatt PR, Conlon JM Peptides, 2026. PMID 41747885
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
ReviewPanou T, Gouveri E, Popovic DS, et al. Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. PMID 42803913
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials
ReviewAlhazmi A, le Roux CW Diabetes, obesity & metabolism, 2026. PMID 42452898
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
ReviewFischer SL, Borner T Pharmacological research, 2026. PMID 42586227
Search used: ("Eloralintide"[tiab]). Run it on PubMed
研究链接
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Eloralintide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.